



ABN 53 075 582 740

ASX ANNOUNCEMENT

23 September 2020

FIRB APPROVAL GRANTED

Bionomics Limited (ASX: BNO, OTCQB:BNOEF), a global, clinical stage biopharmaceutical company, announced today that it has been informed by Apeiron Investment Group Ltd (“Apeiron”), that the Foreign Investment Review Board (“FIRB”) has no objection to Apeiron acquiring up to a 52% interest in Bionomics Limited.

Under the Subscription Agreement dated 1 June 2020 between the Company and Apeiron, Apeiron agreed as part of increasing its shareholding by up to 52%, to underwrite the issue of up to 250,000,000 shares, provided the offer price is not less than \$0.06 and the underwriting obligation does not exceed \$15,000,000, subject to shareholder and FIRB approval.

Shareholder approval was granted at the general meeting held on 26 August 2020 and FIRB approval has now been granted.

Dr De Souza, Executive Chairman of Bionomics said “This is great news which will ensure that the Company has significant funds to progress the second BNC210 Phase 2 clinical trial for the treatment of post-traumatic stress disorder projected for mid 2021. Furthermore, with FIRB approval, Bionomics does not have a ‘going concern’ issue as reported in the 30 June Financial Statements.”

AUTHORISED BY THE EXECUTIVE CHAIRMAN, DR ERROL DE SOUZA.

FOR FURTHER INFORMATION PLEASE CONTACT:

Mr Jack Moschakis
Legal Counsel & Company Secretary
+61 8 8354 6181
jmoschakis@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO, OTCQB:BNOEF) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder (PTSD) and other trauma-related and stressor-related disorders. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.